Who are ezogabine/retigabine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Rogaine, KLH-2109, KAD-1229, Minoxidil lotion 1%, minoxidil 5% solution, Minoxidil lotion 2%.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ezogabine-retigabine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

ezogabine/retigabine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ezogabine/retigabine (ezogabine/retigabine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Potassium channel opener; anticonvulsant. Area: Neurology.

marketed Potassium channel opener; anticonvulsant KCNQ potassium channels (Kv7) Neurology Small molecule Live · refreshed every 30 min

Target snapshot

ezogabine/retigabine (ezogabine/retigabine) — GlaxoSmithKline. Ezogabine opens voltage-gated potassium channels in neurons, increasing potassium efflux and reducing neuronal excitability to suppress seizures.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
ezogabine/retigabine TARGET	ezogabine/retigabine	GlaxoSmithKline	marketed	Potassium channel opener; anticonvulsant	KCNQ potassium channels (Kv7)
Rogaine	minoxidil	Generic (originally Upjohn/Pfizer)	marketed	Vasodilator (potassium channel opener), Hair growth stimulant	ATP-sensitive inward rectifier potassium channel 1, Sulfonylurea receptor 2, Kir6.2	1988-08-18
KLH-2109	KLH-2109	Kissei Pharmaceutical Co., Ltd.	marketed	Potassium channel opener	ATP-sensitive potassium channel
KAD-1229	KAD-1229	Kissei Pharmaceutical Co., Ltd.	marketed	Potassium channel opener	ATP-sensitive potassium channel (KATP)
Minoxidil lotion 1%	Minoxidil lotion 1%	Mae Fah Luang University Hospital	marketed	Potassium channel opener / topical hair growth stimulant	ATP-sensitive potassium channels
minoxidil 5% solution	minoxidil 5% solution	Allergan	marketed	Potassium channel opener	ATP-sensitive potassium channels
Minoxidil lotion 2%	Minoxidil lotion 2%	Mae Fah Luang University Hospital	marketed	Potassium channel opener / topical hair growth stimulant	ATP-sensitive potassium channels (KATP); exact follicle-specific target unclear

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Potassium channel opener; anticonvulsant class)

GlaxoSmithKline · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ezogabine/retigabine — Competitive Intelligence Brief. https://druglandscape.com/ci/ezogabine-retigabine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab